Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MYC amplification as a prognostic marker of early-stage lung adenocarcinoma identified by whole genome copy number analysis.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Mar 2011

Iwakawa Reika, Kohno Takashi, Kato Motohiro, Shiraishi Kouya, Tsuta Koji, Noguchi Masayuki, Ogawa Seishi, Yokota Jun

Abstract excerpt

PURPOSE: Even in small-sized (≤ 2 cm in greatest dimension) and/or pathologic stage I lung adenocarcinoma (ADC), a considerable proportion of the patients will relapse within 5 years and show poor prognosis. The purpose of this study was to identify genetic alterations that define prognosis of patients with early-stage lung ADC. EXPERIMENTAL DESIGN: Regions of copy number alterations in 65 small-sized lung ADCs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Chromosomes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Gene Amplification

Share to Genes, myc

Share to Medical Oncology

Share to Proportional Hazards Models

Share to Proto-Oncogene Proteins c-myc

Source

Identifiers

PMID: 21148746
DOI: 10.1158/1078-0432.CCR-10-2484

Genes

MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MYC amplification as a prognostic marker of early-stage lung adenocarcinoma identified by whole genome copy number analysis.PMID 21148746Read ↗

Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomasSemantic proximity Read ↗

Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I–III Lung AdenocarcinomaSemantic proximity Read ↗

Early-Stage Lung Adenocarcinoma MDM2 Genomic Amplification Predicts Clinical Outcome and Response to Targeted TherapySemantic proximity Read ↗

Characterizing the cancer genome in lung adenocarcinoma.Semantic proximity Read ↗

Genomic Underpinnings of Tumor Behavior in In Situ and Early Lung Adenocarcinoma.Semantic proximity Read ↗

Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors.Semantic proximity Read ↗

Genomic Profiles in Stage I Primary Non Small Cell Lung Cancer Using Comparative Genomic Hybridization Analysis of cDNA MicroarraysSemantic proximity Read ↗

Whole Genome Copy Number Analyses Reveal a Highly Aberrant Genome in TP53 Mutant Lung Adenocarcinoma TumorsSemantic proximity Read ↗

Gene copy number aberrations are associated with survival in histologic subgroups of non-small cell lung cancer.Semantic proximity Read ↗

Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features.Semantic proximity Read ↗

Comparative Genomic Hybridization Array Analysis and Real-Time PCR Reveals Genomic Copy Number Alteration for Lung AdenocarcinomasSemantic proximity Read ↗

Genomic copy number alterations associated with the early brain metastasis of non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.